|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2011-5-23
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
The emergence of artemisinin resistance has raised concerns that the most potent antimalarial drug may be under threat. The currently recommended daily dose of artesunate (AS) is 4 mg/kg, and is administered for 3 days together with a partner antimalarial drug. This study investigated the impact of different AS doses on clinical and parasitological responses in malaria patients from an area of known artemisinin resistance in western Cambodia.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/21603629-10674079,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21603629-11103309,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21603629-12903007,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21603629-15504891,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21603629-15642959,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21603629-17040849,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21603629-18299407,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21603629-18439351,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21603629-19064625,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21603629-19641202,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21603629-19906307,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21603629-20085495,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21603629-20350192,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21603629-21028985,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21603629-21070142,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21603629-781840,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21603629-9576766
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1932-6203
|
|
pubmed:author |
pubmed-author:BethellDeliaD,
pubmed-author:ChanthapLonL,
pubmed-author:DarapisethSeaS,
pubmed-author:FukudaMark MMM,
pubmed-author:GosiPanitaP,
pubmed-author:KhemawootPhisitP,
pubmed-author:KuntawunginWorachetW,
pubmed-author:LinJessicaJ,
pubmed-author:RuttvisutinuntWiriyaW,
pubmed-author:SaundersDavidD,
pubmed-author:SchaecherKurtK,
pubmed-author:SeYouryY,
pubmed-author:SmithBryanB,
pubmed-author:SocheatDuongD,
pubmed-author:SriwichaiSabaithipS,
pubmed-author:Teja-IsavadharmPaktiyaP,
pubmed-author:TimmermansAnsA,
pubmed-author:TynerStuartS
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
6
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
e19283
|
|
pubmed:meshHeading |
pubmed-meshheading:21603629-Adolescent,
pubmed-meshheading:21603629-Adult,
pubmed-meshheading:21603629-Amebicides,
pubmed-meshheading:21603629-Antimalarials,
pubmed-meshheading:21603629-Artemisinins,
pubmed-meshheading:21603629-Cambodia,
pubmed-meshheading:21603629-Dose-Response Relationship, Drug,
pubmed-meshheading:21603629-Drug Resistance,
pubmed-meshheading:21603629-Female,
pubmed-meshheading:21603629-Humans,
pubmed-meshheading:21603629-Malaria,
pubmed-meshheading:21603629-Male,
pubmed-meshheading:21603629-Maximum Tolerated Dose,
pubmed-meshheading:21603629-Neutropenia,
pubmed-meshheading:21603629-Parasitemia,
pubmed-meshheading:21603629-Young Adult
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Artesunate dose escalation for the treatment of uncomplicated malaria in a region of reported artemisinin resistance: a randomized clinical trial.
|
|
pubmed:affiliation |
Department of Immunology and Medicine, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand. delia.bethell@afrims.org
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, Non-P.H.S.,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
